GeneEdit is a biotechnology company focused on developing next-generation gene editing technologies for therapeutic applications. Their proprietary platform aims to enable safer and more precise genome editing for the treatment of various genetic diseases.

GeneEdit

GenEdit is focused on overcoming the major challenge to genetic medicines:  Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.  

The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.


Qiming Venture Partners

SkyDeck Berkeley

Sequoia Capital

Bow Capital

SK Holdings

DCVC Bio

ACVC

Huons

Pathway Partners

Terra VC

Dong-A ST

K2 Investment Partners

KIMCO

Korea Development Bank

loftyrock investment

Mirae Asset Venture Investment

Company K Partners

IMM Investment

Time Folio Asset Management

Timepolio Asset Management

Dayli Partners

Korea Investment Partners

DAOL Investment & Securities

KTB Network

GenEdit

We held an exciting GenEdit Day, which is a recurring event to gather and review our company progress. This year we celebrated our partnership with Genentech, reviewed our latest data and finished the day with a fun team-building activity.


We're excited to announce a collaboration with Genentech to discover and develop novel nanoparticles with our #Nanogalaxy platform to deliver Genentech’s nucleic acid-based medicines for treatment of #autoimmunedisease. 

Read the release here: https://lnkd.in/gvh8J4T6

#geneticmedicines

We are pleased to announce that the GenEdit team is a Phase I winner of the National Institutes of Health TARGETED Challenge for programmable delivery systems for gene editing. The award is a recognition of the potential of our NanoGalaxy® platform for a broad range of genetic medicines for multiple therapy areas.


COM:GENEDIT

GeneEdit

People Not Available